News
Resources
Blog
Sites
Medicare Monday: Medicare Reading List
By Nicole Longo | May 30, 2016
Catching up on your #MedicareMonday reading? Here are a few recent posts on Medicare Part B you don’t want to miss: 3 things to know about the government’s Medicare payment change Part B proposal...
Read More
Week in Review: The latest from PhRMA
By Priscilla VanderVeer | May 27, 2016
Threats to multiple myeloma progress – Progress in the fight against multiple myeloma has led to remarkable results, allowing 80 percent of newly diagnosed patients to live more than four years. Yet...
Read More
ICER framework threatens to halt continued progress against multiple myeloma
By Holly Campbell | May 26, 2016
Progress in the fight against multiple myeloma, a cancer of the blood and bone marrow, has been nothing short of remarkable. Just a decade ago, patients diagnosed faced a poor prognosis and treatment...
Read More
Canada’s promise doctrine strikes again
By Mark Grayson | May 26, 2016
In just the last few weeks Canada has once again taken steps to invalidate yet another medicine (Zymar®) by applying the “promise doctrine.” See Allergan Inc. v. Apotex Inc., 2016 FC 344 (April 1,...
Read More
Many consumers still face confusion around health insurance coverage
By Rebecca Davison | May 25, 2016
Consumers need to be engaged and empowered when making decisions about their health coverage. Two recent studies suggest more can be done to help consumers sort through their health insurance options...
Read More
Cost of mental illness underscores need for new treatments
By Holly Campbell | May 25, 2016
Today, one in five American adults and children experience a mental illness in any given year. As the prevalence of complex mental health conditions has grown, the cost of caring for patients has...
Read More
Medicare Monday: The downside of one-size-fits-all treatment for patients managing mental health conditions
By Nicole Longo | May 23, 2016
In the last couple weeks, we’ve compared the potential impact of using one-size-fits-all standards of care instead of personalized treatment plans for patients with breast cancer and colon cancer. In...
Read More
Higher deductibles and more dissatisfaction with health plans according to new poll
By Karyn Schwartz | May 20, 2016
The share of consumers in a high deductible plan increased from 36 percent to 49 percent among those who purchase their own insurance, according to a new Kaiser Family Foundation poll released today....
Read More
New non-discrimination rule neglects to define discriminatory benefits
By Karyn Schwartz | May 19, 2016
In a final rule released late last week, the Department of Health and Human Services’ Office of Civil Rights declined to provide details on health insurance benefit designs it considers to be...
Read More
The Science of Hope: Understanding biomarkers
By Andrew Powaleny | May 18, 2016
In the age of personalized medicine, biomarkers (short for “biological markers”) are emerging as important tools in drug development. A biomarker is a measure or physical sign that can be used to...
Read More
340B Spotlight: A look at 340B eligibility and charity care
By Allyson Funk | May 17, 2016
Last week the Alliance for Integrity and Reform of 340B (AIR340B)—of which PhRMA is a member—released a new report looking at charity care provided by 340B hospitals. This expands on previous...
Read More
Nearly 4.5 million jobs and counting
By Priscilla VanderVeer | May 17, 2016
At PhRMA, we have the honor of highlighting the hope that America’s biopharmaceutical companies bring to patients in the form of innovative treatments and cures. But beyond the value that medicines...
Read More
Medicare Monday: Why Part D Extra Help matters for patients like Mateo
By Nicole Longo | May 16, 2016
For low-income seniors managing multiple chronic conditions, medical expenses can add up. That’s where the Medicare Part D Extra Help program can make a big difference. As we saw with hypothetical...
Read More
New academic initiative aims to inform approaches to value assessment frameworks
By Holly Campbell | May 13, 2016
As the U. S. health care market continues to shift toward a system that prioritizes and rewards value, there is increasing attention on the development and use of value assessment frameworks. When...
Read More
PhRMA member companies invested $58.8 billion in R&D in 2015
By Stephen J. Ubl | May 12, 2016
For more than 30 years, the U.S. biopharmaceutical industry has been the world leader in the development of new medicines, driving innovation for patients. And PhRMA member companies continue to be...
Read More
Lessons learned: Clinical trials
By Andrew Powaleny | May 9, 2016
A dynamic and collaborative health care ecosystem is crucial to conducting efficient and effective clinical trials, but two-thirds of trials fail to enroll enough participants. Misconceptions and a...
Read More
Medicare Monday: What they’re saying about the CMS proposed Part B payment model
By Nicole Longo | May 9, 2016
Voices throughout the media and health care system have raised concerns with the Part B Drug Payment Model proposed by the Centers for Medicare & Medicaid Services (CMS). News outlets have called...
Read More
New PhRMA Report: Medicines in development for patients with rare diseases demonstrate the promise of innovation
By Ieva M. Augstums | May 9, 2016
Today, there are 7,000 known rare diseases, or diseases that affect fewer than 200,000 people in the United States. But those suffering from the impact of these diseases have more hope today because...
Read More
Week in Review: The latest from PhRMA
By Priscilla VanderVeer | May 6, 2016
Stopping opioid abuse – PhRMA and its members stand with patients, providers, law enforcement, policymakers and others in calling for and supporting national policies and action to address opioid...
Read More
Stopping opioid abuse
By Anne McDonald Pritchett, PhD | May 6, 2016
According to the U.S. Centers for Disease Control and Prevention (CDC), more than 14,000 people died from overdoses involving opioids in 2014—a four-fold increase since 2009. The agency has declared...
Read More
ICYMI - The Economists’ Voice: Are biopharmaceutical budget caps good public policy?
By Holly Campbell | May 6, 2016
In case you missed it, a recent article in The Economists’ Voice examines how assessing the value of medicines using budget caps would impede patient access and chill biopharmaceutical innovation. In...
Read More
A state-by-state look at coverage and access hurdles in 2016 exchange plans
By Rebecca Davison | May 6, 2016
We frequently talk about access barriers patients with health insurance exchange plans face, including two recent studies from Avalere Health and Harvard University Center for Health Law and Policy...
Read More
Strong IP is propelling innovation and saving lives
By Mark Grayson | May 5, 2016
Each day, new medicines are being researched and developed that save lives and improve patients’ quality of life. As the global epicenter of life science innovation and technological breakthroughs,...
Read More
Clinical Trials Q&A: A patient’s perspective
By Jocelyn Ulrich | May 4, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
We are at a pivotal time in health care in America. Biomedical discovery and innovation have the potential to revolutionize the way we diagnose and treat patients. At the same time, rapidly changing...
Read More
New and innovative immunotherapy medicines developed by America’s biopharmaceutical research companies are transforming how we fight cancer and are providing newfound hope to patients. Rather than...
Read More
We’ve highlighted how the proposed Part B model lacks safeguards to protect patients from barriers and reduced quality of care. Some stakeholders have suggested that the Part B proposal looks a lot...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
